The Establishment and Maintenance of a Comprehensive Thoracic Tumor Data Registry and Bioreceptor 
Aims: The purpose of this database is to allow researchers to review and compare medical information including medical history, symptoms, medical test results, treatments and complications that people with thoracic tumor may have. Another purpose of this study is to collect leftover tissue obtained during thoracic surgery or diagnostic tests. Research testing of this tissue may help to determine the changes which lead to the development and/or spread of cancer. This information may help to develop new kinds of diagnostic tests and treatment for thoracic cancer.
Diagnosis: Thoracic Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH98-136
Sponsor: NorthShore University HealthSystem
Contact: Interested patients should contact research coordinator Ujala Bokary at 847.570.1783
Open to Enrollment: Yes

ABI-007-NSCL-005: Safety and efficacy of nab ® -paclitaxel (Abraxane ®) in combination with carboplatin with carboplatin as first line treatment in elderly subjects with advanced non-small cell lung cancer (NSCLC): A Phase IV, randomized, open-label, multicenter study
Aims: This study will compare two schedules of this combination in patietns who are at least 70 years old. The purpose of this study is to find out which nab-paclitaxel/caboplatin schedule is better tolerated and to compare efficacy between the two schedules.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-256
Sponsor: Celgene Corporation
Contact: Interested patients should contact research nurse Michele Britto at 847.570.2109
Open to Enrollment: Yes

S1400: Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Aims: The purpose of this study screening step is to perform genetic tests on your tumor sample for certain features that investigational targeted agents used in this study are specifically designed to work against. Then the purpose is to assign you to a treatment sub-study that is chosen based on the results (genes and proteins called "biomarkers") of this genetic testing on your tumor sample. This study related "research test" will be done in a special lab. The system of assigning a treatment sub-study based on genetic testing of cancer is investigational; in squamous cell lung cancer patients, we don’t know whether testing can identify patients who will or will not benefit from treatment. The purpose of the treatment part of this study is to compare the effects, good and bad, of these investigational agents to the usual approach to treating your type of cancer. It may be possible that you will not be able to participate in the treatment part of this study. This could happen if it is unsafe for you to receive the investigational treatment. You may also choose to not participate in the treatment portion of the study. Before you decide to get treatment on the study, you will be given information about the study treatment and you will be asked if you wish to continue on this research study.
Diagnosis: Squamous Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-415
Sponsor: Southwest Oncology Group
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to Enrollment: Yes

A Prospective Randomized, Controlled, Multi-Center Evaluation of a Powered Vascular Stapler in Video-Assisted Thorascopic Lobectomies
Aims: The study is comparing rates of hemostatic interventions between FDA approved ECHELON FLEX Powered Vascular Stapler with Advanced Placement Tip to the leading Standard of Care vascular stapler used in video-assissted Thorascopic Surgery (VATS) Lobectomy. This study will be recruiting patients iwth suspected or confirmed stage IA to stage IIIA Non-Small Cell Lung Cancer who will be receiving a lobectomy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH15-205
Sponsor: Ethicon Endo-Surgery
Contact: For more information, interested participants may contact Patricia Park at 847.570.1675, ppark@northshore.org
Open to Enrollment: Yes

E4512: Testing the Addition of Deug Crizotinib After Surgery to Remove ALK-Positive Non-Small Cell Lung Cancer: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Aims: The purpose of this research study is to compare any good and bad effects of using the study drug, crizotinib (also known as XALKORI(R)), after completion of surgery and, in some cases, after chemotherapy and/or radiation therapy for ALK-positive non-small cell lung cancer. In addition of crizotinib may help prevent your cancer from returning, but it could also casue side effects. This research study will allow the researchers to know whether this different approach is better, the same, or worse than the usual approach.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-121
Sponsor: ECOG-ACRIN
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A151216: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Aims: The purpose of this research study is to examine lung cancer patients' surgically removed tumors for certain genetic changes, and to possibly refer these patients to a treatment study with drugs that may specificially target tumors that have these genetic changes.
Diagnosis: Resectable or Resected Lung Cancer
Principal Investigator: Ki Wan Kim, MD
IRB Approval Number: EH15-122
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A Multicenter, Randomized Trial of Esophagetcomy and Cervical Esophagogastrostomy With (Two-stage) or Without (One-stage) Prior Ischemic Gastric Conditioning by Laparoscopic Ligation of Left Gastric and Short Gastric Arteries
Aims: The study aims to determine if ischemic gastric preconditioning by cutting part of the blood supply to the stomach several days before the esophagectomy procedure minimizes side effects. It will also examine if there is a difference in the quality of life (QOL) of patients in two arms of the study as assessed by validated questionnaires.
Diagnosis: Surgical candidates for esophageal cancer
Principal Investigator: 
Ki Wan Kim, MD
IRB Approval Number: 
EH15-175
Sponsor:
 NorthShore University HealthSystem
Contact: Interested patients may contact Jen Jaffe, MPH, CCRP at 847.570.2803, jjaffe@northshore.org or Ujala Bokhary, MBBS, CCRP at 847.570.1783, ubokhary@northshore.org  

A081105: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)
Aims: The purpose of this research study is to compare any good and bad effects patients may have when treated with the standard treatment against patients who are treated with the standard treatement against patients who are treated with the standard treatment plus erlotinib (and investigational drug).
Diagnosis: Non-Small Cell Lung Cancer (NSCLC)
Principal Investigator: Ki Wan Kim, MD 
IRB Approval Number: EH15-123
Sponsor: Alliance
Contact: Interested patients should contact research nurse Claudia Fredian, RN at 847.570.1512
Open to Enrollment: Yes

A221303: Randomized Study of Early Palliative Care Integreated with Standard Oncology Care Versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-Colorectal Gastrointestinal Malignancies
Aims: The purpose of this research study is to see whether patients who receive care from palliative care doctors and nurses at an earlier time in their disease, along with their regular cancer care, will experience less emotional and physical issues from their cancer.
Diagnosis: Incurable Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH15-215
Sponsor: Alliance
Contact: Interested patients should contact research nurse Susan Greve, RN at 847.570.1183
Open to Enrollment: Yes

AbbVie M14-359: A Randomized, Open-Label, Multicenter, Phase 2 Trial Comparing Velparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Subjects Receiving First Cytoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who are Current or Former Smokers
Aims: The main purpose of this study is to determine if subjects with advanced or metastatic non-squamous NSCLC repond better with valiparib in combination with carboplatin and paclitaxel compared to Investigator's choice of standard chemotheraoy in subjects with metastatic or advanced non-small cell lung cancer (NSCLC).
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Nicholas Campbell, MD
IRB Approval Number: EH14-401
Sponsor: AbbVie
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

Best Practive in VATS Lobectomy and Segmentectomy for Lung Cancer: A Prospective, Observational, Quality Improvement Study to Optimize Care for Lung Cancer Patients Undergoing Video-Assisted Thoracoscopic Surgery (VATS)
Aims: This is a multi-center study which will be conducted at seven sites. The purpose of this study is to establish a database for doing data and cost analysis of the workup, early treatment and follow-up of patients who have VATS lobectomy or segmentectomy for lung cancer.
Diagnosis: Lung Cancer
Principal Investigator: Seth Krantz, MD
IRB Approval Number: EH13-155
Sponsor: Ethicon Endo Surgery
Contact: Interested participants may contact Ujala Bokhary, MBBS, CCRP at 847.570.1783, ubokhary@northshore.org
Open to Enrollment
: Yes

Clovis CO-1686-020: TIGER-3: A Phase 3, Open Label. Multicenter, Randomized Study of Rociletinib (CO-1686) Monotherapy Versus Single-agent Cytotoxic Chemotherapy in Patients with Mutant EGFR Non-small Cell Lung Cancer (NSCLC) after Failure of at Least 1 Previous EGFR-directed Tyrosine Kinase Inhibitor (TKI) and Platinum-double Chemotherapy
Aims: The purpose is to compare the safety and anti-tumor effects of rociletinib with that of single agent chemotherapy in patients whose tumors did not respond or stopped responding to treatment wtih EGFR TKI and platinum-containing doublet chemotherapy.
Diagnosis: Non-Small Cell Lung Cancer
Principal Investigator: Thomas Hensing, MD
IRB Approval Number: EH14-372
Sponsor: Clovis Oncology, Inc.
Contact: Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment: Yes

AstraZeneca: D4191C00004: A Phase III, Open-Label, Randomized, Multi-centre, International Study of MEDI4735, Given as Monotherapy or in Combination with Tremelimumab, Determined by PD-L1 Expression, Versus Standard of Care in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherarpy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARTIC) Study
Aims:
The main purpose of this study is to determine if the following drugs or combinations of MEDI4736 and/or Tremelimumab respond better  compared to Investigator's choice of standard chemotherapy in subjects with metastatic or advanced non-small cell lung cancer (NSCLC).
Diagnosis: 
Non-Small Cell Lung Cancer
Principal Investigator:
Thomas Hensing, MD
IRB Approval Number:
EH15-070
Sponsor:
AstraZeneca
Contact:
Interested patients should contact research nurse Michele Britto, RN at 847.570.2109
Open to enrollment:
Yes